

## RVG TFA

<b>Cat. No.:</b>	HY-P5623B	
<b>Molecular Formula:</b>	$C_{141}H_{217}N_{43}O_{43} \cdot xC_2HF_3O_2$	
<b>Sequence:</b>	Tyr-Thr-Ile-Trp-Met-Pro-Glu-Asn-Pro-Arg-Pro-Gly-Thr-Pro-Cys-Asp-Ile-Phe-Thr-Asn-Ser-Arg-Gly-Lys-Arg-Ala-Ser-Asn-Gly	
<b>Sequence Shortening:</b>	YTIWMPENPRPGTPCDIFTNSRGKRASNG	YTIWMPENPRPGTPCDIFTNSRGKRASNG (TFA)
<b>Target:</b>	Bacterial	
<b>Pathway:</b>	Anti-infection	
<b>Storage:</b>	Sealed storage, away from moisture and light	
	Powder	-80°C 2 years
		-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

## SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : ≥ 100 mg/mL * "≥" means soluble, but saturation unknown.
-----------------	--

## BIOLOGICAL ACTIVITY

<b>Description</b>	RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AChR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells <sup>[1]</sup> .
--------------------	--

## REFERENCES

[1]. Omar Garnica, et al. Enhanced delivery of Mycobacterium tuberculosis antigens to antigen presenting cells using RVG peptide. Tuberculosis (Edinb). 2019 May;116S:S34-S41.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA